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Abstract
Purpose To date, the interchangeability of generic drugs has
only been investigated for a limited number of medicines. The
objective of this study was to investigate generic-generic drug
interchangeability in a large subset of generic formulations in
order to cover a broad spectrum of drugs.
Methods Orally administered drugs for investigation in this
study were selected using strict, predefined criteria, with the
purpose to avoid bias. This selection procedure yielded ator-
vastatin, bicalutamide, naratriptan, olanzapine, perindopril,
and venlafaxine. Further, ciclosporin, tacrolimus, and myco-
phenolate mofetil were investigated as test immunosuppres-
sants. Adjusted indirect comparisons were conducted between
generic drugs containing the same active substance, and the
90 % confidence interval (CI) for AUC and Cmax was
calculated.
Results In total, 120 bioequivalence studies were identified in
the Dutch medicine regulatory agency’s database, allowing
292 indirect comparisons between generic drugs. The indirect
comparison results indicated that in the vast majority of cases,
i.e., 80.5 %, the 90 % CIs for both AUCt and Cmax fell within
the bioequivalence criteria (in 90.1 and 87.0 % for AUCt and
Cmax, respectively). In 1 % of the 292 indirect comparison for
AUCt and 3 % for Cmax, a wider range of 75–133 % (or 80–
125 %) was exceeded.
Conclusions Overall, our study suggests that exposure-related
risks associated with the exchange of different generic drugs
in clinical practice are not increased to a relevant extent com-
pared to the situation in which a generic is exchanged with the
innovator.
Keywords Generic drugs . Interchangeability .
Bioequivalence . Pharmacokinetics
Introduction
A generic medicinal product is considered to be therapeutical-
ly equivalent to the innovator. To be registered, one or more
so-called bioequivalence studies are required to demonstrate
that the 90 % confidence interval (CI) for the generic/
innovator ratios of the area under the drug concentration-
time curve (AUC) and the maximum concentration (Cmax) is
within the range of 80–125 % [1–4]. This acceptance range of
80–125 % can be widened based on a scaled approach for
Cmax up to 69.84–143.19 % for highly variable drugs or can
be tightened to 90–111.11 % for narrow therapeutic index
drugs (NTIDs).
At present, for most active pharmaceutical ingredients
(APIs), multiple generic products have been approved in the
Netherlands, and regular switches from one generic product to
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another are seen in clinical practice. From a regulator’s per-
spective, generic-generic drug switching is unlikely to impact
treatment, as all generic formulations have been shown to be
bioequivalent to the innovator product, and thus, the deviation
of drug exposure between generic products should be limited
[5]. Based on that, generic products are considered to be suf-
ficiently comparable to each other. However, current regula-
tion does not require bioequivalence studies between different
generic formulations. In fact, in theory, a Bdrift^ may appear
upon generic-generic drug substitution, meaning that generic
formulations that are bioequivalent to the innovator drug, re-
spectively, may not be bioequivalent to each other [6]. This
potential problem is due to the acceptance range for generic
product registration (90 % CIs of AUC and Cmax ratios within
the 80–125 % range), which allows small variations in expo-
sure between generic and innovator drugs. Thus, if one gener-
ic product has a higher and another has a lower exposure level
than the innovator drug, the difference between the generic
drugs will be reinforced, potentially leading to bio-
inequivalence between them. In addition, the possibility of
the occurrence of bio-inequivalence between generic drugs
is also shown in theoretical Monte Carlo simulation studies
[7, 8]. Therefore, investigation into this generic-generic drug
comparability is warranted.
In light of the discussion about the drift upon generic drug
substitutions, we have previously conducted indirect compar-
isons to evaluate generic-generic drug interchangeability
using gabapentin and topiramate as test medications [9]. As
a result, in general, bioequivalence between the different ge-
neric gabapentin and topiramate formulations was demon-
strated. These interstudy comparison results were subsequent-
ly confirmed and validated by a clinical bioequivalence study
using multiple generic formulations of gabapentin [10].
Furthermore, in the public domain, the comparability and
safety of generic immunosuppressants, typically in transplan-
tation medicines, are hot topics of discussion [11–17].
Therefore, this study is conducted to investigate the accept-
ability of generic-generic drug interchangeability for a broad
spectrum of medicines as well as immunosuppressants based
on the bioequivalence studies submitted for registration.
Methods
Drug selection
For this study, only orally administrated tablets or capsules
with systemic action were considered relevant. The database
at Dutch medicine regulatory agency was used for drug selec-
tion and data collection. To avoid a selection bias, a period of
January 1 to May 9, 2008 was predefined to create a cohort,
which contains all APIs that had at least one generic formula-
tion (tablets or capsules) registered during this period,
regardless of the type of registration procedure. Second, the
identified APIs were ordered according to the registration date
starting from January 1, 2008. In order to largely predict the
interchangeability of currently marketed generic drugs, it was
predefined to select the first six APIs from the initial cohort
that had more generic drugs registered after January 1, 2008
(until June 8, 2010). In addition to this predefined selection,
we also decided to investigate cyclosporine, tacrolimus, and
mycophenolate mofetil as test immunosuppressants, triggered
by the debate in the field on generic drugs from this class. For
all selected APIs, bioequivalence studies in the registration
files of generic formulations before January 1, 2012 were
retrieved from the Dutch medicine regulatory agency’s
database.
Data analysis
Adjusted indirect comparisons between generic products con-
taining the same API were conducted. This method has been
well used in this kind of research, since it allows an estimation
of the 90 % CI based on an interstudy comparison. The major
limitation is that the uncertainty (i.e., standard error) of the
indirect comparison is larger than the standard error of any
of the studies under comparison, which is expected to be also
larger than the standard error in case two generic drugs are
directly compared in a study. It therefore leads to an overesti-
mation of the differences between generic drugs (i.e., broader
90 % CIs than calculated in a direct comparison). Thus, the
adjusted indirect comparison method is considered as a con-
servative approach and is expected to provide reliable results
in the case that the adjusted indirect comparison indicates the
90%CIs within the acceptance range of 80–125%, as verified
by an in vivo bioequivalence study [10]. In addition,
analogous to the method used in the direct comparison,
the chosen indirect comparison method is an average
bioequivalence approach, which allows to compare the
results of the indirect comparisons with the results of
in vivo bioequivalence studies, because this is the crite-
rion used for the studies for generic drug registration.
Thus, this method is preferred over other methods rec-
ommended in literature based on population and indi-
vidual bioequivalence approach [18, 19] and scaled av-
erage bioequivalence approach [20].
The indirect comparisons were only made between two
generic formulations when their bioequivalence studies used
the same dose, design, and conditions (i.e., either fasting/fed
and/or either crossover/parallel). In line with recommenda-
tions by Gwaza et al.[21], a pragmatic method based on t test
was used (see the algorithm below). This method has been
shown to give comparable results as the homoscedastic meth-
od. All analyses were performed using Excel, Microsoft
Office 2010®.
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Algorithms
All calculations were based on ln-transformed data. The ratios
between two generic formulations (G2/G1) for AUC (AUC0-t
for single dose studies and AUC for one dosing interval at
steady state for multiple-dose studies) and Cmax were calcu-
lated by subtraction of the ln-transformed generic/innovator
ratios in one bioequivalence study (RBE1) from the ratios in
another bioequivalence study (RBE2), which gives the adjusted
difference between G1 and G2:
lnR G2=G1ð Þ ¼ lnRBE2−lnRBE1 ð1Þ
The 90 % CIs were calculated as follows:
SE dð Þ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SE21 þ SE222
q
; d: f : ¼ n1 þ n2−2ð Þ ð2Þ
ln−transformed90%CI ¼ lnR G2=G1ð Þ  t d fð Þ  SE dð Þ ð3Þ
The standard errors from the ANOVA model in the bio-
equivalence studies (SE1 and SE2) were used to estimate the
standard error (SE(d)) in the indirect comparison of G2 and
G1. Degrees of freedom (d.f.) were estimated as the sum of
subjects from the two bioequivalence studies (n1 and n2) mi-
nus two, and student’s t distribution t-percentiles t(d.f.) were
used. The exponentiated results from Eqs. 1 and 3 were used
to judge bioequivalence between generics.
Definition of bioequivalence
The European Medicines Agency (EMA) guidelines [2, 22]
regarding bioequivalence were followed, i.e., 90 % CIs for
both AUC and Cmax of a generic drug with immediate
release properties should meet the 80–125 % criterion.
Further guidance on NTIDs was adhered for cyclospor-
ine, tacrolimus, and mycophenolate mofetil [23]. The
tightened acceptance range of 90–111 % was applied
for both AUC and Cmax for cyclosporine, and only
AUC for tacrolimus. Bioequivalence of generic myco-
phenolate mofetil was demonstrated based on the plas-
ma concentration of mycophenolic acid, and the 80–
125 % criterion was followed.
Results
Following the selection criteria, atorvastatin, bicalutamide,
naratriptan, olanzapine, perindopril, and venlafaxine were in-
cluded for this study. Further, the immunosuppressants cyclo-
sporine, tacrolimus, and mycophenolate mofetil were includ-
ed. Overall, eight of the selected APIs were immediate release
formulations, whereas one, i.e., venlafaxine, was an extended
release formulation.
Clinical bioequivalence studies
For the selected 9 APIs, 115 brands of generic drugs were
identified, which were registered based on 120 bioequivalence
studies in total (Table 1). A number of different brands of
generic products were registered based on the same dossier,
i.e., the same bioequivalence study(ies). The generic/
innovator ratios for AUC and Cmax in the 120 studies ranged
from 90.0 to 116.7 % and from 87.7 to 118.5 %, respectively.
The mean absolute deviation of the ratios from 100 % in this
set of generics was 4.5 % for AUC and 5.1 % for Cmax, re-
spectively. The ranges of the lower and upper boundary of the
90%CIs for AUC and Cmax over the available bioequivalence
studies are summarized for every API and strength in Table 1.
Adjusted indirect comparisons between generic drugs
In total, 292 indirect comparisons between generic drugs were
conducted based on 116 bioequivalence studies. Four bio-
equivalence studies could not be used as they were the only
bioequivalence study for a specific strength of APIs (Table 2).
In 80.5 % (235 out of 292) of the comparisons, the 90 % CIs
for both AUC and Cmax fell within the 80–125 % (or 90–
111 %) acceptance range. In 90.1 % (263 out of 292) and in
87.0 % (254 out of 292) of the comparisons, the estimated
90 % CIs were within the predefined acceptance range for
AUC and Cmax, respectively (Table 2).
Area under the plasma concentration-time curve (AUC)
The estimated generic/generic ratios for AUC ranged from
84.2 to 120.4 % (Fig. 1a). The mean absolute deviation of
the ratios from 100 % in this set of generic drugs was 5.4 %.
The individual lower and upper boundaries of 90 % CIs for
AUC varied in the ranges of 72.9–111.9 and 91.6–134.1 %,
respectively (Fig. 2a).
All generic-generic 90 % CIs for AUCwere within the 80–
125 % acceptance criterion for atorvastatin, mycophenolate
mofetil, naratriptan, olanzapine, and perindopril. For relative-
ly few comparisons (29 out of 292, see Fig. 2a and Table 2),
90 % CIs for generic-generic AUC ratios did not meet the 80–
125 % (or 90–111 %) criterion. The level by which the margin
of 80 or 125% (or 90 or 111%)was exceeded ranged from 0.1
to 12.1%. Twenty-six of these 29 cases did not exceed a wider
range of 75–133% (or 80–125%). Thus, overall, in 1% of the
292 indirect comparisons for AUCt, a wider range of 75–
133 % (or 80–125 %) was exceeded.
Maximum plasma concentration (Cmax)
The generic/generic ratios for Cmax ranged from 78.1 to 124.5 %
(Fig. 1b) based on the indirect comparisons. The mean absolute
deviation of the ratios from100% in this set of generic drugswas
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6.1 %. The individual lower and upper boundaries of 90 % CIs
for Cmax ranged from 70.2 to 112.5 % and from 84.9 to 140.1%,
respectively. Similar with the situation for AUC, in the majority
of generic-generic drug comparisons, a 90 % CI for Cmax within
the acceptance ranges was obtained (Fig. 2b and Table 2). A
90 % CI exceeding the 80–125 % margin (or 90–111 %) was
observed for 38 of the 292 comparisons (Table 2). The level by
which the margin of 80 or 125% (or 90 or 111%) was exceeded
ranged from 0.1 to 15.4%. Twenty-nine of these 38 cases did not
exceed a wider range of 75–133% (or 80–125%). Thus, overall,
in 3% of the 292 indirect comparisons for Cmax, a wider range of
75–133 % (or 80–125 %) was exceeded.
Discussion
Based on the presented results, bioequivalence between ge-
neric drugs can be concluded in 80.5 % of the cases. In 90.1%
of the comparisons, the 90 % CI of the ratios was within the
80–125 % (or 90–111 %) range for AUC and in 87.0 % for
Cmax. Although bioequivalence was not formally demonstrat-
ed in 19.5 % of the cases with 90 % CIs outside the 80–125 %
(or 90–111 %) margin (either AUC or Cmax), bio-
inequivalence, potentially resulting in clinical consequences,
was not demonstrated either. In this investigation, the adjusted
indirect comparison combines the variability from both bio-
equivalence studies (Eq. 2). Therefore, the comparison results
generally yield broader 90 % CIs for AUC and Cmax between
generic drugs, compared to the 90 % CIs obtained in actual
clinical bioequivalence studies [9, 21]. According to Glenny
et al. [24], the SE of the indirect estimate can be expected to be
about 1.41 larger than that of the direct estimate. This suggests
that when the 90%CIs are obtained just outside the 80–125%
(or 90–111 %) margin (for instance within a wider range of
75–133 %, or 80–125 %), the actual 90 % CIs in a direct
comparison situation of a bioequivalence study may well be
within the acceptance range. Therefore, a failure of showing
bioequivalence in our study does not demonstrate that the
investigated generic drugs are not bioequivalent. In addition,
the study results show that only 3 cases (1.0 %, n=292) for
AUC and 9 cases (3.1 %, n=292) for Cmax can be considered
as extreme cases, i.e., exceeding the wider 75–133 % (or 80–
125 %) criterion. Although our results cannot fully eliminate
uncertainty regarding generic-generic interchangeability,
since formal bioequivalence between generics was not dem-
onstrated in all cases, no cases of bio-inequivalence were not-
ed in our comparisons.
Potential clinical relevance of observed differences
for AUC and Cmax
Overall, the generic/generic ratios and 90 % CIs for Cmax
showed a larger variation than AUC in every API, and moreTa
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estimations yielded 90 % CIs outside the acceptance criterion
for Cmax. Cmax is generally considered to be less critical than
AUC for concluding therapeutic equivalence [23, 25]. In most
cases, the requirement for Cmax aims to regulate the safety
profile of the generic formulations. It suggests that in most
cases, clinical consequences are not expected when bioequiv-
alence cannot be demonstrated for Cmax with a relatively small
magnitude of difference. For this reason, regulatory
Fig. 1 Calculated ratios of generic-generic drug comparisons for a AUC
and b Cmax (n=292). Dots in blue represent the generic/generic ratios (Y-
axis) at every comparison group (the same design with the same strength
of APIs) (X-axis) for which the 90 % CIs were within the acceptance
ranges; circles in black represent for the ratios of their 90 % CIs outside
the margin. At the X-axis, the group is labeled by API, strength and the
study design if not single dose, fasting or crossover
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authorities (e.g., EMA and FDA) allow using a widened ac-
ceptance range for Cmax for highly variable drugs [26, 25].
Specific API-related issues on the clinical relevance of 90 %
CIs outside the 80–125 % margin (see Table 2) are discussed
below.
Atorvastatin
For atorvastatin, deviations from the 80–125 % criterion were
only seen for Cmax (Table 2). Bio-inequivalence was not indi-
cated in our comparisons. As discussed above, atorvastatin is a
Fig. 2 Boxplots of the calculated generic/generic ratios and 90% CIs for
a AUC and b Cmax for each API (n=292). The boxplot in yellow and in
blue represents the distribution of upper and lower boundary of 90 % CIs
for every API (X-axis), respectively. The boxplot in green represents the
ratios. Reference lines (red) represent limits of the acceptance range re-
quired by the EMA
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well-known highly variable drug (i.e., intrasubject variability
>30 %), so a widened acceptance range (75–133 %) may be
used [27]. Although the intrasubject variability is not known
for the specific bioequivalence studies, this possibility sug-
gests that exceeding of the 80–125 % may not be clinically
relevant per se. Further, the magnitude of all exceeded cases
was relatively small, i.e., within the range of 75–133%, which
supports that these cases are unlikely to be clinically relevant.
In the literature, generic atorvastatin products have been
shown to have comparable treatment outcomes with the inno-
vator drug and were well-tolerated [28], and no significant
differences in efficacy, adverse events, and patient manage-
ment were seen upon clinical substitution [29, 30].
Bicalutamide
The elimination half-life of bicalutamide is very long
(5–6 days) [31]. In patients, bicalutamide is given daily
(50 mg tablet), after which an increase of the plasma
concentration by 10-fold occurs as a consequence of the
long half-life. As a result, the difference in Cmax in
single dose exposure between the generics is expected
to be limited in actual clinical treatments. In addition,
the 16 cases of 90 % CIs for AUC outside the 80–
125 % margin appeared only in the comparisons of
parallel studies. As the 90 % CIs are wider in a parallel
design study due to intersubject variability, the likeli-
hood of obtaining such 90 % CIs outside the margin
is higher for this type of study. Further, despite this
increased likelihood, the magnitude of all exceeded
cases was relatively small, i.e., within the range of
75–133 %, which suggests that these cases may not be
clinically relevant.
Cyclosporine
For cyclosporine, both generic formulations were registered
based on the 80–125% criterion, because they were registered
before the EMA requirements on narrowed acceptance ranges
for this drug [23] came into force. However, one of the two
bioequivalence studies as support for registration of the cyclo-
sporine generics actually fulfilled the 90–111 % range. It is
obvious that the indirect comparison cannot meet the tight-
ened acceptance range of 90–111 %.
The exceeded case is noted in Table 2, where the 90 % CI
for AUC was within a wider range of 80–125 %, but the Cmax
(94.5–126.5 %) exceeded the margin. The adverse events of
cyc lospor ine were sc reened in the da tabase of
The Netherlands Pharmacovigilance Centre Lareb, and no po-
tential events related to formulation switching were found.
However, it is acknowledged that pharmacovigilance data-
bases like the one from Lareb suffer from under-reporting.
Also, the fact that generic-generic exchange is not expected
to occur regularly for this drug may add to the lack of reports
regarding the issues for generic cyclosporine drugs. Thus,
although bio-inequivalence is not indicated by our results, it
is uncertain if the deviation from the 90 % acceptance criteria
for cyclosporine leads to a different benefit-risk in the clinic.
Tacrolimus
Due to a long and variable elimination half-life of 11–16 h in
the patients [32, 23], an accumulation of tacrolimus concen-
tration would be expected in treatment and thus a difference in
single dose Cmax level is not expected to clinically impact the
treatment. According to other literature [33–36], therapeutic
equivalence between the innovator and generic tacrolimus has
been observed without safety concerns. In clinical practice,
dose titration is required for tacrolimus treatment in organ
transplant patients. Therefore, therapeutic equivalence be-
tween different generic tacrolimus drugs is also likely to be
the case under such dose titration, and clinical consequences
due to our observed minor exceeding in AUC over the 90–
111 % limits based on the estimation (Table 2) are not
expected.
Venlafaxine
As venlafaxine is an extended release formulation, the phar-
macological properties are more sensitive to limited differ-
ences in the generic drugs compared with immediate release
formulation. This could lead to widespread 90 % CIs upon
generic-generic drug substitution of venlafaxine. The
exceeded cases are noted in Table 2, in which one case for
AUC and seven cases for Cmax exceeded a wider range of 75–
133 %, which indeed indicates an uncertainty related to clin-
ical consequences. However, for extended release formula-
tions, the demonstration of bioequivalence under three condi-
tions is required by EMA, i.e., single dose fasting and fed and
steady state [2, 37, 22]. In our study, for most comparisons
between generic drugs, bioequivalence under only one of the
requested conditions could not be demonstrated. This situa-
tion is quite different from the immediate release formulation
where only one pivotal bioequivalence study is requested.
Since in all cases, bioequivalence is demonstrated under dif-
ference situations, the probability of inequivalence under only
one condition affecting clinical outcomes is expected to be
limited. Of note, FDA requires only bioequivalence under
single-dose fed condition for the registration of venlafaxine
generic drugs; thus, the situation of interchangeability for
venlafaxine generic drugs in the USA can be different from
Europe [38]. In literature, bio-inequivalence in fasted state for
venlafaxine 75 mg has been reported between the generic and
the innovator drug approved by FDA [39].
In this study, an initial cohort of APIs was defined based on
the registration date of generic drugs, which was considered to
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be independent of bias, for instance potential difficulties of
demonstration of bioequivalence. The initial cohort contained
a large number of APIs (n=21), allowing a valid selection from
the cohort. The selected 6 APIs from the initial cohort are not
considered to be the easy cases in terms of the demonstration of
bioequivalence, for instance, atorvastatin, bicalutamide, and
venlafaxine. A selection bias (except for the immunosuppres-
sants that were included in the study) is not expected.
Furthermore, the selected APIs had large numbers of generic
drugs, e.g., atorvastatin (18 generic brands), bicalutamide (18),
olanzapine (20), and venlafaxine (19) (Table 1). Although the
selected APIs may not be the APIs with the largest number of
generic drugs, they can still be considered to be representative
to a general pattern of registered generic drugs.
The study results are in line with our previous study [9] and
comparative bioavailability study [10] for investigation into
the generic-generic interchangeability of topiramate and
gabapentin. Furthermore, for tacrolimus, our findings are in
line with a similar study performed by Herranz et al. [40].
Consistently, when considering all 120 bioequivalence studies
in this investigation, the mean absolute deviation of the ratios
from 100 % in this set of generics was 4.5 % for AUC and
5.1 % for Cmax. These figures are also comparable with the
results of a study from the FDA [5], which showed that the
mean absolute deviation from 100% for AUC and Cmax being
3.6 and 4.4 %, respectively. In our opinion, strengthened by
justified unbiased selection of drugs, it is reasonable to assume
that our estimation of generic-generic interchangeability from
this study can be generalized as an overall pattern for a larger
group of registered generic medicines.
Recently, a retrospective study reported a significant differ-
ence in serum level between generic phenytoin drugs and an
increased seizure event rate following switching from one to
other generic drug in Korean patients [41]. However, the pos-
sible selection bias was not justified for the study. The patients
for whom the records of serum phenytoin levels were avail-
able may have been more susceptible for instable treatment
effects, resulting in higher risk of seizures. Furthermore, the
causal relationship between the generic phenytoin switching
and decrease in serum level (and increase in seizure events)
cannot be concluded, since it is unclear when the serum phe-
nytoin levels were recorded, what daily dose was administrat-
ed and which generic drug was used in the pre- and post-
interchange period in every patient. Thus, further research is
warranted for the generic drugs involved in that study, and the
conclusion may not be extrapolated to other generic drugs. In
some papers, it is proposed that for registration, generic drugs
should not only be compared to their innovator, but also to
other generics that are already on the market. In our opinion,
such a request would not be realistic. Further, this would even
need to be repeated when another generic is applied for. Based
on the outcome of this study, the actual chance of having a
90 % CI outside the criteria upon exchange of generics in
direct comparisons is expected to be small. However, the pos-
sibility of exceeding the 80–125 % margin in the real life
conditions cannot be excluded. Of note, the 80–125 % crite-
rion is not directly linked to efficacy or safety. Thus, exceed-
ance of the 80–125 %margin cannot be directly interpreted as
resulting in clinical consequences per se.
Conclusion
Based on a conservative approach, our study demonstrates that
more than 80 % of the registered generic drugs were not only
bioequivalent to the innovator but also to each other. Due to
methodological constraints in our comparison, the 90 % CIs
obtained in this study are generally larger than in the actual
within-study comparisons. Therefore, we expect that the actual
percentage of generics being bioequivalent to other generics in
the actual clinical setting will be higher than 80 %. However,
our results also imply that formal bioequivalence between ge-
nerics could not be demonstrated in maximally 20 % of the
cases. Still, the magnitude by which the 90 % CIs boundary is
exceeded should not be interpreted as the actual difference
between generic drugs in clinical practice [21], and in the vast
majority of the cases, the exceedance of the acceptance criteria
is limited. Further, although bioequivalence could not be dem-
onstrated in some cases, in none of the cases the reverse, i.e.,
bio-inequivalence was demonstrated. Thus, although the re-
sults are not fully reassuring, we consider a pronounced risk
upon generic-generic exchange in clinical practice as unlikely.
Overall, our study suggests that exposure-related risks associ-
ated with the exchange of different generic drugs in clinical
practice is limited, and not much increased—if any—to the
situation in which a generic is exchanged with the innovator.
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